MGN 3

Drug Profile

MGN 3

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiwa Pharmaceutical
  • Developer Daiwa Pharmaceutical; Lane Labs
  • Class Antineoplastics; Antivirals
  • Mechanism of Action B cell stimulants; Immunostimulants; Interleukin 10 stimulants; Interleukin 6 stimulants; Interleukin 8 modulators; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lyme disease
  • No development reported Cancer; HIV infections

Most Recent Events

  • 08 Apr 2003 No development reported - Phase-II for Cancer in USA (unspecified route)
  • 08 Apr 2003 No development reported - Preclinical for HIV infections treatment in USA (unspecified route)
  • 03 Apr 2001 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top